News

Dr Adashi, a physician-scientist-executive with over 25 years of experience in healthcare and in the life sciences was also appointed to serve as a member of the board’s

Regeneron Pharmaceuticals, a biopharmaceutical company, has initiated patient enrollment in the Phase III program evaluating the efficacy and safety of Arcalyst, also known as interleukin-1 trap, in the

Under the terms of the agreement, Altea Therapeutics has granted Lilly and Amylin exclusive worldwide rights to develop and commercialize transdermal exenatide utilizing the Altea Therapeutics proprietary PassPort

The alliance allows Patheon and Kemwell to refer and market each others’ services to clients to better meet their respective client’s requirements. The alliance is effective immediately and

Arena Pharmaceuticals has announced positive top-line results from Bloom, the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management. Statistical significance (p<0.0001)

Avidas Pharmaceuticals, a specialty pharmaceutical company which focuses on dermatology and women’s health, has launched the Scalacort defence kit that offers three scalp solutions in one patient convenience

Dor BioPharma, an R&D biopharmaceutical company, has entered into a $400,000 common stock equity investment agreement priced at market with its clinical trials management partner, Numoda, a provider

Australia-based biotechnology company Avexa has reported that the last patient enrolled in the initial two dose phase of the apricitabine Phase III trial has passed the week 16

Novavax intends to use the $11 million in gross proceeds from this investment to pay a portion of its 4.75% senior convertible notes due in July 2009 and